Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.

Inclusion Criteria: * Patient with a confirmed diagnosis of active moderate to severe HS (Hurley Score 2-3) * Male or Female adult patients ≥ 18 years of age at the time of data collection * Patient newly initiated on Secukinumab (first dose to coincide within 1 month of the signature of the informed consent) * Patients with a diagnosis of HS who are currently using antibiotics/ have undergone surgery or not as part of their routine clinical management are eligible for inclusion. * Patients with a diagnosis of HS who have a history of previous treatment with Adalimumab or any other anti-TNF agent as part of their routine clinical management or biologic naïve are eligible for inclusion. * Agreed to sign an informed consent to be able to fill in the questionnaires. Exclusion Criteria: * Patients not fulfilling any of the abovementioned inclusion criteria. * Patient's refusal to be included in the study or refusal to sign the informed consent.